newsfilter
← Latest News
ACCESS Newswire·

Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

- Continued progress with the DNase-based oncology program towards Phase 1 study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors- Ended the quarter with $12.0 million of